An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Smith, David H ^a,b   Christensen, Ib J ^c   Jensen, Niels F ^b   Markussen, Bo ^d   Müller, Sven ^a   Nielsen, Hans J ^b,e   Brünner, Nils ^b   Nielsen, Kirsten V ^a,f  

^a AGILENT TECHNOLOGIES   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e HVIDOVRE HOSPITAL   (Denmark)

^f Research and Innovation Centre   (Denmark)

Author keywords

Colorectal cancer; ERCC1; ERCC4; FISH; Prognosis; XPF

Indexed keywords

BIOLOGICAL MARKER; ESTERASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 4; PLACEBO; RANITIDINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CHROMOSOME 19Q; COHORT ANALYSIS; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; COPY NUMBER VARIATION; EXPLORATORY RESEARCH; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; HUMAN CELL; HUMAN TISSUE; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; METAPHASE; MOLECULAR PROBE; OVERALL SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SURVIVAL RATE;

AGE FACTORS; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 19; COHORT STUDIES; COLORECTAL NEOPLASMS; DNA COPY NUMBER VARIATIONS; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; NEOPLASM STAGING; PATIENT OUTCOME ASSESSMENT; SEX FACTORS;

EID: 84885761260     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-489     Document Type: Article

References (38)

1. Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG, Trevino AV, et al. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000, 58:920-927.
2. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33:9-23. 10.1016/j.ctrv.2006.09.006, 1855222, 17084534.
3. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008, 14:1291-1295. 10.1158/1078-0432.CCR-07-2238, 18316546.
4. Wood RD. DNA repair in eukaryotes. Annu Rev Biochem 1996, 65:135-167. 10.1146/annurev.bi.65.070196.001031, 8811177.
5. Niedernhofer LJ, Odijk H, Budzowska M, van DE, Maas A, Theil AF, et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 2004, 24:5776-5787. 10.1128/MCB.24.13.5776-5787.2004, 480908, 15199134.
6. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001, 19:4298-4304.
7. Koopman M, Venderbosch S, van TH, Ligtenberg MJ, Nagtegaal I, Van Krieken JH, et al. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer 2009, 45:1999-2006. 10.1016/j.ejca.2009.04.017, 19457654.
8. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008, 26:2690-2698. 10.1200/JCO.2007.15.5580, 18509181.
9. Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, et al. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol 2009, 32:38-43. 10.1097/COC.0b013e31817be58e, 19194123.
10. Bhagwat NR, Roginskaya VY, Acquafondata MB, Dhir R, Wood RD, Niedernhofer LJ. Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res 2009, 69:6831-6838. 10.1158/0008-5472.CAN-09-1237, 2739111, 19723666.
11. Ma D, Baruch D, Shu Y, Yuan K, Sun Z, Ma K, et al. Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology. BMC Biotechnol 2012, 12:88. 10.1186/1472-6750-12-88, 3526464, 23171216.
12. Yu JJ, Bicher A, Ma YK, Bostick-Bruton F, Reed E. Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues. Cancer Lett 2000, 151:127-132. 10.1016/S0304-3835(99)00390-0, 10738106.
13. Liang BC, Ross DA, Reed E. Genomic copy number changes of DNA repair genes ERCC1 and ERCC2 in human gliomas. J Neurooncol 1995, 26:17-23. 10.1007/BF01054765, 8583241.
14. Vanhecke E, Valent A, Tang X, Vielh P, Friboulet L, Tang T, et al. 19q13-ERCC1 Gene copy number increase in non-small-cell lung cancer. Clin Lung Cancer 2013, 14:549-557. 10.1016/j.cllc.2013.01.006, 23773262.
15. Nielsen KV, Brunner N. Re: topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst 2011, 103:352-353. 10.1093/jnci/djq528, 21217082.
16. Smith DH, Christensen IJ, Jensen NF, Markussen B, Romer MU, Nygard SB, et al. Mechanisms of topoisomerase I (TOP1) gene copy number increase in a stage III colorectal cancer patient cohort. PLoS One 2013, 8:e60613. 10.1371/journal.pone.0060613, 3618421, 23577133.
17. Romer MU, Nygard SB, Christensen IJ, Nielsen SL, Nielsen KV, Muller S, et al. Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis. Mol Oncol 2012, 7(1):101-111.
18. Nielsen HJ, McArdle C, Moesgaard F, The RANX05 Study Group The effect of ranitidine on long-term survival on primary colorectal cancer. A 40 months interim analysis. GI Cancer 1998, 227-233. The RANX05 Study Group.
19. Matthiesen SH, Hansen CM. Fast and non-toxic in situ hybridization without blocking of repetitive sequences. PLoS One 2012, 7:e40675. 10.1371/journal.pone.0040675, 3404051, 22911704.
20. Roschke AV, Tonon G, Gehlhaus KS, McTyre N, Bussey KJ, Lababidi S, et al. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 2003, 63:8634-8647.
21. Ghadimi BM, Sackett DL, Difilippantonio MJ, Schrock E, Neumann T, Jauho A, et al. Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. Genes Chromosomes Cancer 2000, 27:183-190. 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P, 10612807.
22. The Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337. 10.1038/nature11252, 3401966, 22810696, The Cancer Genome Atlas Network.
23. Knosel T, Schluns K, Stein U, Schwabe H, Schlag PM, Dietel M, et al. Genetic imbalances with impact on survival in colorectal cancer patients. Histopathology 2003, 43:323-331. 10.1046/j.1365-2559.2003.01720.x, 14511250.
24. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci USA 2007, 104:20007-20012. 10.1073/pnas.0710052104, 2148413, 18077431.
25. Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, et al. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature 2008, 455:547-551. 10.1038/nature07179, 2587138, 18794900.
26. Bamberger AM, Methner C, Lisboa BW, Stadtler C, Schulte HM, Loning T, et al. Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive tumor phenotype. Int J Cancer 1999, 84:533-538. 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J, 10502734.
27. Laska MJ, Lowe SW, Zender L, Hearn S, Vogel U, Jensen UB, et al. Enforced expression of PPP1R13L increases tumorigenesis and invasion through p53-dependent and p53-independent mechanisms. Mol Carcinog 2009, 48:832-842. 10.1002/mc.20528, 3328301, 19263435.
28. Sin WC, Zhang Y, Zhong W, Adhikarakunnathu S, Powers S, Hoey T, et al. G protein-coupled receptors GPR4 and TDAG8 are oncogenic and overexpressed in human cancers. Oncogene 2004, 23:6299-6303. 10.1038/sj.onc.1207838, 15221007.
29. Beghini A, Magnani I, Roversi G, Piepoli T, Di TS, Moroni RF, et al. The neural progenitor-restricted isoform of the MARK4 gene in 19q13.2 is upregulated in human gliomas and overexpressed in a subset of glioblastoma cell lines. Oncogene 2003, 22:2581-2591. 10.1038/sj.onc.1206336, 12735302.
30. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 2000, 290:989-992. 10.1126/science.290.5493.989, 11062132.
31. Leung N, Turbide C, Olson M, Marcus V, Jothy S, Beauchemin N. Deletion of the carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam1) gene contributes to colon tumor progression in a murine model of carcinogenesis. Oncogene 2006, 25:5527-5536. 10.1038/sj.onc.1209541, 16619040.
32. Nittka S, Gunther J, Ebisch C, Erbersdobler A, Neumaier M. The human tumor suppressor CEACAM1 modulates apoptosis and is implicated in early colorectal tumorigenesis. Oncogene 2004, 23:9306-9313. 10.1038/sj.onc.1208259, 15568039.
33. Rychahou PG, Kang J, Gulhati P, Doan HQ, Chen LA, Xiao SY, et al. Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis. Proc Natl Acad Sci USA 2008, 105:20315-20320. 10.1073/pnas.0810715105, 2629319, 19075230.
34. Kontos CK, Papadopoulos IN, Scorilas A. Quantitative expression analysis and prognostic significance of the novel apoptosis-related gene BCL2L12 in colon cancer. Biol Chem 2008, 389:1467-1475.
35. Bulow S, Harling H, Iversen LH, Ladelund S. Improved survival after rectal cancer in Denmark. Colorectal Dis 2010, 12:e37-e42.
36. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005, 23:7518-7528. 10.1200/JCO.2005.00.471, 16172461.
37. Deloia JA, Bhagwat NR, Darcy KM, Strange M, Tian C, Nuttall K, et al. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum. Gynecol Oncol 2012, 126:448-454. 10.1016/j.ygyno.2012.05.006, 3518863, 22609620.
38. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.